Hospital Acquired Infection Control Market by Type, Indication, End-user

Description

List of Tables

[194 Pages Report] The Hospital Acquired Infection Control Market size was estimated at USD 34.26 billion in 2023 and expected to reach USD 36.39 billion in 2024, at a CAGR 6.48% to reach USD 53.20 billion by 2030.

Hospital acquired infection (HAI) control refers to the systematic approach and dedicated efforts undertaken by healthcare institutions to prevent and manage infections acquired by patients during their stay in hospitals & other healthcare facilities. These infections can occur as a result of exposure to various microbial agents, including bacteria, viruses, fungi, and other pathogens. The control measures span a wide range of strategies, including rigorous hygiene practices, sterilization and disinfection procedures, use of personal protective equipment (PPE), surveillance of infections, and adherence to protocols for invasive procedures and antibiotic stewardship. The rising awareness about infections acquired in healthcare settings, coupled with a rapidly growing emphasis on infection control policies, boosts the market growth. However, high costs associated with advanced infection control technologies can be prohibitive for resource-limited settings. Furthermore, technological advancements in sterilization and disinfection processes, along with the development of eco-friendly and more efficient disinfectants, pose significant opportunities to the manufacturers.

KEY MARKET STATISTICS
Base Year [2023]	USD 34.26 billion
Estimated Year [2024]	USD 36.39 billion
Forecast Year [2030]	USD 53.20 billion
CAGR (%)	6.48%

Type: Ongoing technological advancements in diagnostic and testing equipment to increase efficiency

Diagnostic and testing equipment constitute critical components in the identification and management of hospital-acquired infections (HAIs). This segment includes devices and kits used for the rapid detection of pathogens in clinical settings. Leveraging advanced technologies, such as polymerase chain reaction (PCR) and enzyme-linked immunosorbent assay (ELISA), this equipment helps in the early diagnosis and monitoring of infections, enabling timely intervention and treatment. Disinfection products play a pivotal role in preventing the spread of infections within healthcare facilities. Disinfection products encompass a wide range of chemical and non-chemical agents designed to destroy or inactivate infectious organisms on various surfaces. Among these are disinfectants, sterilants, and antiseptics, which are used on medical equipment, hospital beds, and other high-touch areas to maintain a sterile environment and minimize the risk of infection transmission. Hand hygiene products are essential in the battle against HAIs, given that hand transmission is a major pathway for the spread of infections. This category includes antibacterial hand washes, hand rubs, and sanitizers, which are formulated to effectively kill germs and prevent the colonization of harmful bacteria on the hands of healthcare workers, patients, and visitors. Personal Protective Equipment (PPE) consists of garments and gear designed to protect healthcare workers and patients from being exposed to infectious agents. PPE includes items such as masks, gowns, and face shields, which act as barriers to the transmission of infections. Especially crucial during outbreaks of highly contagious diseases, PPE is instrumental in reducing the spread of HAIs and safeguarding the health of individuals within the healthcare environment. Sterilization equipment encompasses autoclaves, heat sterilizers, and low-temperature sterilizers, crucial for rendering medical instruments and devices pathogen-free. Factors such as cycle time, capacity, and energy efficiency govern their preference.

End-user: Hospitals & ICUs emphasize comprehensive and automated solutions for high-risk environments

Ambulatory surgical & diagnostic centers are characterized by their short-term patient care for surgical and diagnostic procedures. The need for HAI control in these centers focuses on efficient sterilization equipment and practices, given the high throughput of patients and the necessity for quick turnaround times. Hospitals and Intensive Care Units (ICUs) are the epicenters for treating critical patients, making HAI prevention paramount. These facilities require comprehensive infection control solutions that encompass air filtration, surface disinfection, and stringent sterilization protocols. Nursing homes and maternity centers, while differing in patient demographics, share concerns over the vulnerability of their populations to HAIs. Infection control in these settings emphasizes gentle yet effective disinfection methods and products that are safe for long-term exposure.

Regional Insights

The Americas, led by the United States and Canada, exhibit a robust demand for HAI control solutions, attributed to stringent regulatory standards and a high level of healthcare expenditure. Innovation and technological advancement are key factors, with a focus on non-toxic, eco-friendly disinfection methods and smart monitoring systems. In the European Union, stringent regulations and a focus on accreditation and quality in healthcare drive the demand for high-standard HAI control solutions. EU-wide initiatives aim at harmonizing infection control practices, enhancing cross-border cooperation in HAI research, and fostering innovation. The Middle East is witnessing a healthcare transformation, with significant investments in hospital infrastructure and quality improvement initiatives. There is an increasing demand for advanced infection control technologies, albeit with a preference for cost-effective solutions in some countries. The Asia Pacific region is noted for its rapid adoption of advanced HAI control solutions, driven by growing healthcare infrastructure and heightened awareness of infection-prevention protocols. China and Japan are prominent countries in APAC with substantial investments in R&D, while India is emerging as a substantial market due to its increasing number of hospitals and focus on healthcare quality. Customer purchasing behavior in this region leans towards integrated solutions offering both cost efficiency and effectiveness.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Hospital Acquired Infection Control Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Hospital Acquired Infection Control Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Hospital Acquired Infection Control Market, highlighting leading vendors and their innovative profiles. These include 3M Company, Abbott Laboratories, Advanced Sterilization Products Services Inc., AHLSTROM OYJ, Becton, Dickinson and Company, Belimed AG, Cantel Medical Corporation by STERIS PLC, Cardinal Health, Inc., DNV AS, Ecolab Inc., F. Hoffmann-La Roche Ltd, GOJO Industries, Inc., Henkel AG & Co. KGaA, Kimberly-Clark Corporation, Medline Industries, LP, Olympus Corporation, Sterigenics International LLC, and Unilever PLC.

Market Segmentation & Coverage

This research report categorizes the Hospital Acquired Infection Control Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type
- Diagnostic & Testing Equipment
- Disinfection Products
- Hand Hygiene Products
- Personal Protective Equipment
- Sterilization Equipment

Indication
- Bloodstream Infections
- Clostridioides difficile Infections
- Hospital-acquired Pneumonia
- Multidrug-Resistant Organisms
- Surgical Site Infections
- Urinary Tract Infections

End-user
- Ambulatory Surgical & Diagnostic Centers
- Hospitals & ICUs
- Nursing Homes & Maternity Centers

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Hospital Acquired Infection Control Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Hospital Acquired Infection Control Market?

3. What are the technology trends and regulatory frameworks in the Hospital Acquired Infection Control Market?

4. What is the market share of the leading vendors in the Hospital Acquired Infection Control Market?

5. Which modes and strategic moves are suitable for entering the Hospital Acquired Infection Control Market?

Product Code: MRR-035590447FE4

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Rising awareness about infections in healthcare settings with growing emphasis on infection control policies
  - 5.1.1.2. Growing prevalence of chronic diseases with increasing geriatric population
  - 5.1.1.3. Increasing use of disinfectants and medical nonwovens in the healthcare industry
- 5.1.2. Restraints
  - 5.1.2.1. High cost associated with the endoscope reprocessors and microbial testing instruments
- 5.1.3. Opportunities
  - 5.1.3.1. Increasing investments in R&D coupled with high usage of consumables in hospitals
  - 5.1.3.2. Technological advancements in sterilization & disinfection processes and infection control devices
- 5.1.4. Challenges
  - 5.1.4.1. Concerns associated with the safety of reprocessed instruments
5.2. Market Segmentation Analysis
- 5.2.1. Type: Ongoing technological advancements in diagnostic and testing equipment to increase efficiency
- 5.2.2. End-user: Hospitals & ICUs emphasize comprehensive and automated solutions for high-risk environments
5.3. Market Disruption Analysis
5.4. Porter's Five Forces Analysis
- 5.4.1. Threat of New Entrants
- 5.4.2. Threat of Substitutes
- 5.4.3. Bargaining Power of Customers
- 5.4.4. Bargaining Power of Suppliers
- 5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis

6. Hospital Acquired Infection Control Market, by Type

6.1. Introduction
6.2. Diagnostic & Testing Equipment
6.3. Disinfection Products
6.4. Hand Hygiene Products
6.5. Personal Protective Equipment
6.6. Sterilization Equipment

7. Hospital Acquired Infection Control Market, by Indication

7.1. Introduction
7.2. Bloodstream Infections
7.3. Clostridioides difficile Infections
7.4. Hospital-acquired Pneumonia
7.5. Multidrug-Resistant Organisms
7.6. Surgical Site Infections
7.7. Urinary Tract Infections

8. Hospital Acquired Infection Control Market, by End-user

8.1. Introduction
8.2. Ambulatory Surgical & Diagnostic Centers
8.3. Hospitals & ICUs
8.4. Nursing Homes & Maternity Centers

9. Americas Hospital Acquired Infection Control Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Hospital Acquired Infection Control Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Hospital Acquired Infection Control Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
- 12.3.1. Ahlstrom launches Reliance Fusion next-generation simultaneous sterilization wrap
- 12.3.2. PAMA introduces new ethylene oxide sterilisation solution
12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

13.1. Key Company Profiles
13.2. Key Product Portfolio